Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7284-7293

  Natrajan, Rachael ^a   Little, Suzanne E ^a   Reis Filho, Jorge S ^b   Hing, Lara ^a   Messahel, Boo ^a   Grundy, Paul E ^b,c   Dome, Jeffrey S ^d   Schneider, Toni ^e   Vujanic, Gordan M ^f   Pritchard Jones, Kathy ^a   Jones, Chris ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; MESSENGER RNA; PROTEIN CACNA1E; UNCLASSIFIED DRUG;

ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; EARLY RESPONSE GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CALCIUM CHANNELS, R-TYPE; CATION TRANSPORT PROTEINS; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; EARLY GROWTH RESPONSE PROTEIN 1; EARLY GROWTH RESPONSE PROTEIN 2; EARLY GROWTH RESPONSE PROTEIN 3; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, WILMS TUMOR; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MAP KINASE KINASE 5; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-FOS; RECURRENCE; WILMS TUMOR;

EID: 33846250804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1567     Document Type: Article

References (29)

1. Kalapurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol 2004;5:37-46.
2. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005;23:7312-21.
3. Hoglund M, Gisselsson D, Hansen GB, Mitelman F. Wilms tumors develop through two distinct karyotypic pathways. Cancer Genet Cytogenet 2004;150:9-15.
4. Gow KW, Murphy JJ. Cytogenetic and histologic findings in Wilms' tumor. J Pediatr Surg 2002;37: 823-7.
5. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2002;38:11-21.
6. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001;158:393-8.
7. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210:49-58.
8. Lu YJ, Hing S, Williams R, et al. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002;360:385-6.
9. Williams RD, Hing SN, Greer BT, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004;41:65-79.
10. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat Genet 2001;29:365-71.
11. Westphall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: John Wiley and Sons (Chichester, United Kingdom); 1993.
12. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86: 398-408.
13. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36:299-303.
14. Weiergraber M, Pereverzev A, Vajna R, et al. Immunodetection of α1E voltage-gated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem 2000;48:807-19.
15. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
16. 2+ channel α1E-subunit. Eur J Neurosci 1998;10:916-25.
17. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4: 249-64.
18. 2+ channel α1 subunits in cell lines and tissues. Eur J Biochem 1998;257:274-85.
19. Terasawa K, Okazaki K, Nishida E. Regulation of c-Fos and Fra-1 by the MEK5-5 pathway. Genes Cells 2003;8:263-73.
20. Savelyeva L, Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett 2001;167:115-23.
21. Pereverzev A, Mikhna M, Vajna R, et al. Disturbances in glucose-tolerance, insulin-release, and stress-induced hyperglycemia upon disruption of the Ca(v)2.3 (α1E) subunit of voltage-gated Ca(2+) channels. Mol Endocrinol 2002;16:884-95.
22. Wang XT, Nagaba Y, Cross HS, et al. The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 2000;157:1549-62.
23. 2+ channels. Annu Rev Cell Dev Biol 2000; 16:521-55.
24. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21.
25. 2+ channel expression. Biochem Biophys Res Commun 2004;322:1359-63.
26. Diaz-Meco MT, Moscat J. MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling. Mol Cell Biol 2001;21:1218-27.
27. 2+ channel. Cell Physiol Biochem 2006;17: 97-110.
28. Mehta PB, Jenkins BL, McCarthy L, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression, and invasion. Oncogene 2003;22:1381-9.
29. McNaughton NC, Davies CH, Randall A. Inhibition of α(1E) Ca(2+) channels by carbonic anhydrase inhibitors. J Pharmacol Sci 2004;95:240-7.